AbbVie Inc. $ABBV Stake Boosted by BDF Gestion

BDF Gestion raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 28.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 44,504 shares of the company’s stock after buying an additional 9,982 shares during the period. AbbVie accounts for 1.2% of BDF Gestion’s portfolio, making the stock its 10th biggest position. BDF Gestion’s holdings in AbbVie were worth $10,169,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ABBV. Chelsea Counsel Co. acquired a new position in AbbVie during the 3rd quarter valued at about $26,000. Texas Capital Bancshares Inc TX purchased a new stake in AbbVie in the third quarter valued at about $31,000. Evolution Wealth Management Inc. acquired a new stake in AbbVie in the second quarter worth about $26,000. Caitlin John LLC purchased a new stake in shares of AbbVie during the third quarter worth about $33,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of AbbVie during the third quarter worth about $41,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.08% of the company’s stock.

AbbVie Stock Down 0.1%

AbbVie stock opened at $204.89 on Tuesday. The stock has a 50-day moving average price of $222.79 and a 200 day moving average price of $224.80. The company has a market capitalization of $362.29 billion, a price-to-earnings ratio of 86.82, a price-to-earnings-growth ratio of 0.71 and a beta of 0.34. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the company earned $2.16 EPS. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Piper Sandler increased their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Evercore dropped their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. Finally, Barclays started coverage on shares of AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.